Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab (Mabscale) vs Humira in Plaque Psoriasis
NCT06005532Phase 3Recruiting
- Sponsor
- Mabscale
- Start
- Oct 2023
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of adalimumab in plaque psoriasis, sponsored by Mabscale. Started Oct 2023; status: recruiting.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06005532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005532.